Biogen Inc (NASDAQ:BIIB) stock had a fantastic start to September with a 15% rally. But in the past few days of trading, it gave back about one-third of it. Source: Biogen via YouTube Clearly, this is a momentum stock, so it will never give …
Al 11% RIF represents close to 880 employees among the more than 8,000 total workforce. Biogen stock is down 22% this year as Tecfidera sales have slowed down and the sector has slumped. The firm announced on Wednesday it will …
The company revealed Tuesday that it will spin off its hemophilia business into a new ... Since its debut, AbbVie's stock price has risen by nearly 76%, while that of its parent advanced by a comparatively less impressive 20%. The as-yet …
Biogen Idec Inc. (BIIB) was a big mover last session with shares rising over 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend for the company …
Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …
The entire biotech group fell hard since its historic rally from 2009-2015 but is not trying to rally again. The stock is prone to big moves after reporting earnings and …
Dec 21 Biogen Inc said on Thursday one of its drug to treat Alzheimer's disease failed to meet the main goal of a mid-stage trial, sending the drugmaker's shares down 4.3 percent in premarket trading.
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets …
(Reuters) - Biogen Inc's second-quarter profit smashed estimates on Tuesday, boosted by strong sales of its spinal muscular atrophy (SMA) drug, Spinraza, which is priced at $750,000 for the first year of therapy. Buoyed by the …